Funded Startups in Sebastopol
Sebastopol’s most recent funded entries show a sharp disclosed-size split: Traditional Medicinals closed a $50M Private Equity round on 2022-10-01, and no…
Sebastopol’s most recent funded entries show a sharp disclosed-size split: Traditional Medicinals closed a $50M Private Equity round on 2022-10-01, and no other disclosed amount in the five-row set is close. The remaining disclosed rounds cluster much lower at $13M (Bachan's, 2022-09-08) and then $1M (LeafWorks, 2023-06-12) and $250K (Txtsmarter, 2023-04-13), while DNA Compass (2024-07-01) is undisclosed.
Sector and timing are also uneven. Four of five companies list “Series Unknown” (DNA Compass on 2024-07-01; LeafWorks 2023-06-12; Txtsmarter 2023-04-13; Traditional Medicinals is the only one with a named “Private Equity” classification on 2022-10-01; Bachan's is the only “Series A” on 2022-09-08). The disclosed rounds span 2022-09-08 to 2023-06-12, while the newest entry is DNA Compass in July 2024, extending the visible temporal edge beyond the main disclosed cluster.
Most recent rounds
5 shownRelated listings
Frequently asked
What is the largest disclosed round in Sebastopol here, and how does it compare to the rest of the disclosed amounts?
Traditional Medicinals’ $50M Private Equity round (2022-10-01) is the largest disclosed amount in the set, with all other disclosed rounds far below—$13M for Bachan's (2022-09-08), then $1M for LeafWorks (2023-06-12) and $250K for Txtsmarter (2023-04-13). DNA Compass (2024-07-01) is undisclosed, so comparisons rely on the disclosed rows.
Is there a cluster of deal dates, or are rounds spread out across the period shown?
The strongest cluster is concentrated between 2022-09-08 and 2023-06-12, driven by Bachan's (2022-09-08), Traditional Medicinals (2022-10-01), Txtsmarter (2023-04-13), and LeafWorks (2023-06-12). The calendar extends with DNA Compass at 2024-07-01, creating a later outlying timestamp in an otherwise 2022–2023-heavy window.
How dominant are undisclosed and “Series Unknown” classifications in this Sebastopol slice?
Two entries are not comparable on amount disclosure/labeling: DNA Compass is “undisclosed” (2024-07-01). On the stage label, 4 of 5 rows are “Series Unknown” (DNA Compass 2024-07-01; LeafWorks 2023-06-12; Txtsmarter 2023-04-13; Traditional Medicinals is the only named classification aside from Bachan's), leaving only Bachan's as “Series A” (2022-09-08).
Which stage labels appear, and does the list suggest any stage concentration?
Stage information is sparse and skewed toward unknowns: 4 of 5 rows show “Series Unknown,” while only one row is “Series A” (Bachan's, 2022-09-08) and only one is “Private Equity” (Traditional Medicinals, $50M on 2022-10-01). The named-stage deals are also the ones with the largest disclosed amounts.
Are any sectors over-represented among these five entries, and are there clear sector outliers tied to deal size?
No sector repeats in this five-row view: Artificial Intelligence (DNA Compass), Biotechnology (LeafWorks), Information Technology (Txtsmarter), Health Care (Traditional Medicinals), and Food and Beverage (Bachan's). The clearest size outlier by disclosed amount is Health Care via Traditional Medicinals’ $50M (2022-10-01), which dwarfs the next-highest disclosed round in a different sector ($13M for Food and Beverage on 2022-09-08).
Which companies fall within the most recent 90-day window relative to the newest date shown here (2024-07-01)?
Only DNA Compass (2024-07-01) is within a 90-day window ending on the newest date shown. The other four rows fall earlier: LeafWorks (2023-06-12), Txtsmarter (2023-04-13), Traditional Medicinals (2022-10-01), and Bachan's (2022-09-08).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.